Results of IPH2101 Phase I trial in AML published in BLOOD

• 23 patients, median age 71, in first complete remission, received escalating doses of IPH2101
• Conclusions support the rationale behind the recently announced multicentre, double-blind, Phase II trial of anti-KIR mAb vs placebo to be initiated in this patient population
  
  

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the results of the Phase I trial of IPH2101 (hybridoma anti-KIR antibody) in elderly patients with Acute Myeloid Leukemia in first complete remission were published online in the journal Blood.